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The main cause of mortality after the first year from cardiac transplantation is cardiac allo-
graft vasculopathy (CAV†), which leads to chronic rejection of the heart. To improve long-
term outcomes in cardiac transplantation, treatments to prevent or diminish CAV are actively
being researched. Ischemia-reperfusion (I-R) injury has been shown to be the strongest al-
loantigen-independent factor in the development of CAV. Here, we investigate the use of
metformin in murine cardiac transplantation models as a novel cardioprotective agent to
limit acute I-R injury and subsequent chronic rejection. We show that metformin treatment
activates AMP-activated kinase (AMPK) in vitro and in vivo. In the acute transplantation
model, metformin activation of AMPK resulted in significantly decreased apoptosis in cardiac
allografts on postoperative day (POD) 1 and 8. In the chronic transplantation model, met-
formin pretreatment of allografts led to significantly improved graft function and significantly
decreased CAV, as measured on POD 52. Taken together, our results in the acute and
chronic rejection studies suggest a potential cardioprotective mechanism for metformin; we
demonstrate a correlation between metformin-induced decrease in acute I-R injury and met-
formin-related decrease in chronic rejection. Thus, one of the ways by which metformin and
AMPK activation may protect the transplanted heart from chronic rejection is by decreasing
initial I-R injury inherent in donor organ preservation and implantation. Our findings suggest
novel therapeutic strategies for minimizing chronic cardiac rejection via the use of metformin-
and AMPK-mediated pathways to suppress acute I-R injury.
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Almost 6 million people in the United
States have heart failure [1], a subset of which
does not respond to even maximal medical
therapy. The only definitive treatment for
these patients with end stage heart failure is
cardiac transplantation. The main cause of
mortality after the first transplant year is car-
diac allograft vasculopathy (CAV), or chronic
rejection [1]. In order to improve long-term
outcomes in cardiac transplantation, treat-
ments to prevent or diminish CAV are ac-
tively being researched. Ischemia-reperfusion
(I-R)  injury  has  been  shown  to  be  the
strongest alloantigen-independent factor in
the development of CAV [2,3]. Much atten-
tion has been given to metformin and its po-
tential  cardioprotective  property  of
decreasing I-R injury. Metformin is one of the
most  commonly  prescribed  anti-diabetic
drugs for Type 2 diabetes patients. In the
United Kingdom Prospective Diabetes Study
(UKPDS)  of  diabetic  patients,  metformin
usage was found to decrease the risk of my-
ocardial infarction by 14 percent and decrease
the likelihood of heart failure by 16 percent
[4]. These observations were confirmed in
isolated rat hearts, where metformin reduced
cardiac functional loss and acutely improved
cardiac function after ischemia [5]. However,
there are currently no defined molecular path-
ways for metformin’s cardioprotective prop-
erties.  Recent  literature  suggests  that  the
therapeutic effects of metformin may be me-
diated by activation of AMP-activated pro-
tein  kinase  (AMPK)  [6],  an  endogenous
signaling enzyme and master regulator of en-
ergy homeostasis [7].
As shown in Figure 1, AMPK is a het-
erotrimeric molecule that sensitively detects
changes in the AMP/ATP ratio. Upon bind-
ing two molecules of AMP, AMPK is acti-
vated through phosphorylation by several
upstream  kinases  (AMPKK),  including
LKB1  (liver  kinase  B1)  and  CaMKK
(calmodulin dependent protein kinase ki-
nase) [8]. AMPK is activated by stressors
that increase the AMP/ATP ratio, such as
glucose deprivation, ischemia and hypoxia,
and exercise and skeletal muscle contrac-
tion. Once activated, AMPK has a diverse
array of effects, including, but not limited to,
inhibition of biosynthesis (hepatic fat syn-
thesis, muscle glycogen synthesis, and pro-
tein  synthesis),  cell  cycle  arrest  in  G1
through activation of p53-p21 system, and
upregulation of catabolism (skeletal muscle
glucose  uptake,  glycolysis  in  cardiomy-
ocytes, and fatty acid oxidation) [8]. 
AMPK  activation  by  metformin  has
been observed in hepatocytes, skeletal mus-
cle,  and  cardiomyocytes  [9].  In  LKB1
knockout mice, metformin is not as effica-
cious in lowering blood glucose [10], sug-
gesting that AMPK activation is necessary
for metformin’s therapeutic actions. In cul-
tured bovine aortic endothelial cells, met-
formin dose-dependently activates AMPK
by  increasing  the  phosphorylated,  active
form,  and  increasing  the  association  of
AMPK with LKB1, its upstream kinase [11].
Therefore, metformin is likely to increase
AMPK activation by facilitating the phos-
phorylation process. The interplay of met-
formin and AMPK yields cardioprotective
results. In cultured canine cardiomyocytes,
metformin  prevents  cell  death  through
AMPK activation. Similarly, in dog models
of heart failure, metformin promotes phos-
phorylation of AMPK, decreases apoptosis,
and generally improves function of the fail-
ing hearts [12]. The cardioprotective bene-
fits  of  metformin  are  mimicked  with
addition of AMPK agonist AICAR [6] and
abrogated in AMPK knockout mice. Conse-
quently, in the context of heart disease, met-
formin’s cardioprotective benefits may be
mediated by AMPK.
There has been extensive research elu-
cidating AMPK’s role in cardioprotection
from I-R injury. During periods of hypoxia,
AMPK  directly  phosphorylates  cardiac
phosphofructokinase  2  (PFK2)  and  in-
creases uptake of glucose through Glut4
translocation, stimulating glycolysis in the
cardiomyocytes [10]. Besides serving as a
substrate for glycolysis, the increased glu-
cose  flux  also  can  stimulate  the  pentose
phosphate pathway to generate NADPH and
reduced glutathione, which neutralize the re-
active oxygen species (ROS) generated in I-
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with a kinase dead (KD) AMPK, the heart
functions normally before ischemia, but dur-
ing ischemia, in vitro KD hearts cannot up-
take  glucose  and  perform  glycolysis.
Furthermore, the KD hearts have increased
apoptosis and necrosis compared to control
hearts [14]. In another transgenic mouse
study, isolated hearts from transgenic mice
with  dominant  negative  ʱ  subunits  of
AMPK have impaired left ventricular re-
covery of systolic function after I-R injury
[15]. Therefore, AMPK protects hearts from
I-R injury by sustaining energy supply dur-
ing ischemic stress and reducing the likeli-
hood of cardiomyocyte cell death.
The  cardioprotective  effects  of  met-
formin and AMPK may also be applicable
in cardiac transplantation and chronic organ
rejection. AICAR (an AMPK agonist), ap-
plied before and during cardiac transplanta-
tion, resulted in decreased patient mortality
and myocardial injury, as well as improved
clinical outcomes [9]. We hypothesize that
metformin protects the allograft by activat-
ing AMPK. AMPK can prevent cardiomy-
ocyte death from I-R injury by sustaining
energy  supply  during  ischemic  stress,
thereby reducing apoptosis in allografts. By
decreasing initial I-R injury, metformin and
AMPK  activation  may  then  lead  to  de-
creased CAV and improved chronic rejec-
tion outcomes. Metformin is a novel agent
to reduce chronic rejection due to CAV by
limiting I-R related cell death. Metformin
preconditioning and control of acute car-
diomyocyte cell death in allografts has the
potential to delay development of chronic
cardiac rejection, by means other than im-
mune suppression.
MATeRIAls AND MeThoDs
Acute Transplantation Study
All animal protocols were approved by
the Administrative Panel on Laboratory Ani-
mal Care at Stanford University and followed
the NIH and USDA Guidelines for the Care
and Use of Animals in Research. Our Stan-
ford  protocol  number  is  21536.  FVB/NJ
donor hearts were heterotopically transplanted
into C57BL/6J mice (MHC I and II mis-
match). There were three treatment condi-
tions: metformin (Bristol-Myers Squibb, New
York  City,  NY),  AICAR/AMPK  agonist
(Sigma-Aldrich, St. Louis, MO), or PBS con-
trol/vehicle (Sigma-Aldrich, St. Louis, MO).
FVB/NJ donor hearts were first precondi-
tioned with their respective treatment solution
(metformin, AICAR, or PBS control). Treat-
ment included: 1) an intraperitoneal (IP) in-
jection in the donor animal 1 hour prior to
surgery; 2) vena cava injection 2 minutes be-
fore donor organ procurement; and 3) immer-
sion  of  donor  organ  in  treatment  solution
during the cold-ischemia time (approximately
30 minutes). Following the heterotopic heart
transplant, recipient mice were given IP in-
jection of treatment solution every other day.
Donor hearts were harvested on postoperative
day (POD) 1 and 8 (n = 4 for each time point
and treatment condition). Protein extract was
collected through cell lysis, centrifugation,
and protease inhibitor treatment. Experimen-
tal method is summarized in Figure 2.
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Figure 1. AMPK signaling pathway. When stressors, such as hypoxia and glucose depri-
vation, or agonists, such as AICAR, increase AMP levels, AMP binds AMPK cooperatively.
AMPK is then activated through phosphorylation by LKB1. Active phosphorylated AMPK
inhibits biosynthesis and stimulates fatty acid oxidation and glycolysis to maintain energy
supply during ischemia.Chronic Transplantation Study
To assess CAV development, we per-
formed murine heterotopic heart transplan-
tations  using  a  MHC  Class  II  mismatch
model.  B6.C-H2-Ab1bm12/KhEg-Mc1re-J/J
donor  hearts  were  heterotopically  trans-
planted into littermate control C57BL/6J
mice. Graft viability and beat score was as-
sessed by direct abdominal palpation daily.
Allografts were harvested on POD 52, with
n = 6 for each group. Morphometric analy-
sis was performed using Image J software
(NIH) to assess luminal narrowing (intimal
proliferation). Percent luminal narrowing =
(area bounded by internal elastic lamina ―
area bounded by lumen)/area bounded by in-
ternal elastic lamina * 100 percent.
SDS-PAGE and Western Blot Analysis
Protein concentrations from graft protein
extracts were determined through the bicin-
choninic acid assay (ThermoScientific Pierce,
Waltham, MA) according to manufacturer pro-
tocol. Sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) was performed
using 10 ﾵg of protein from each graft per well.
Western blot was performed with the following
primary antibodies: rabbit ʱ vinculin (Sigma-
Aldrich, St. Louis, MO), rabbit ʱ AMPK, rabbit
ʱ phospho-AMPK, mouse ʱ caspase-9, mouse ʱ
caspase-8, and rabbit ʱ Bax (Cell Signaling
Technologies, Beverly, MA). Quantification by
densitometry was performed using Image J. 
Other Protein Assays
To quantify cell death, histone-associ-
ated DNA levels in the protein extracts were
measured  using  the  cell  death  detection
ELISA (Roche, Indianopolis, IN) using 10 ʼg
of protein in duplicates, according to manu-
facturer protocol. To assay caspase-3 activity
in protein extracts, the caspase-3 fluorometric
assay (R&D Systems, Minneapolis, MN) was
performed using 100 ʼg of protein in dupli-
cates. The reporter molecule 7-amino-4-tri-
fluoromethyl coumarin is cleaved by active
caspase-3, resulting in a fluorochrome that
emits fluorescence at 505 nm when excited at
400 nm. 
In Vitro Studies
A well-developed cell culture system
was used for studying I-R injury. Immortal-
ized cardiomyocytes (HL-1 cells) were pre-
treated  with  combinations  of  metformin,
AICAR, Compound C (AMPK antagonist),
and PBS vehicle and then exposed to hy-
poxic conditions with 1 percent O2, 5 per-
cent CO2, and 94 percent N2 for 45 minutes.
Cell lysates were captured at 24 hours, and
protein extract was collected through cell
lysis, centrifugation, and protease inhibitor
treatment.
Statistical Analysis
Statistical tests of differences between
the treatment groups were performed with
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Figure 2. experimental schematic for acute transplantation study. The three treat-
ment groups, each with n=4, were: metformin, AICAR, and vehicle (PBS). Treatment was
administered to donor mouse preoperatively, as well as to recipient mouse postopera-
tively. Grafts were harvested on POD 8 for protein based assays.two tailed, unpaired Student’s T Test without
the assumption of equal variances, with p <
0.05 considered significant. All data were
presented as mean ﾱ standard error (SEM).
ResulTs
Metformin Treatment 
Results in AMPK 
Activation in Human 
Endothelial Cells In Vitro
HL-1 cell cultures were
utilized to demonstrate the ef-
fects of metformin on AMPK
activation in vitro.Metformin-
and AICAR-treated hypoxic
cells showed dramatically in-
creased active phosphorylated
AMPK (pAMPK) protein lev-
els  compared  to  vehicle-
treated cells, as detected by
Western blot analysis (Figure
3a).  However,  total  AMPK
levels  did  not  change,  sug-
gesting that both metformin
and AICAR lead to activation
of the AMPK signaling path-
way by increasing the phos-
phorylated,  active  form  of
AMPK. 
The AMPK-activating ef-
fects  of  metformin  and
AICAR  were  abolished  by
adding Compound C, an ATP-
competitive  antagonist  of
AMPK. When Compound C
was combined with metformin
or AICAR, the cells showed a
decrease  in  pAMPK  com-
pared to metformin or AICAR
alone (Figure 3a), indicating
that  both  metformin  and
AICAR  exert  their  function
through the phosphorylation of
AMPK.
Metformin Treatment 
Results in Activation of
AMPK in Cardiac Allografts
In Vivo
In  addition  to  demon-
strating  metformin  activa-
tion of AMPK in vitro, we determined that
metformin also activates AMPK in vivo.
Protein lysates from allografts harvested on
POD 8 were utilized to demonstrate the ef-
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Figure 3. Metformin mediated cardioprotection through
AMPK activation. a) Western blot analysis for active phos-
phorylated AMPK (pAMPK), total AMPK, and vinculin load-
ing control using protein from in vitro hypoxic cardiomyocytes
treated with metformin, metformin and compound C (AMPK
antagonist), AICAR (AMPK agonist), AICAR and compound
C, or vehicle (PBS). b) Western blot analysis for active phos-
phorylated AMPK (pAMPK), total AMPK, and vinculin load-
ing control using protein from POD 8 graft hearts treated with
vehicle (PBS), metformin or AICAR. c) Schematic of various
caspases involved in intrinsic and extrinsic apoptosis. d)
Western blot analysis for Bax and loading control vinculin
using protein from POD 8 graft hearts treated with vehicle
(PBS), metformin or AICAR. e) Western blot analysis for cas-
pase-9 and loading control vinculin using protein from POD
8  graft  hearts  treated  with  vehicle  (PBS),  metformin  or
AICAR. f) Caspase-3 fluorescent activity assay using protein
from POD 8 graft hearts treated with vehicle (PBS), met-
formin or AICAR. Values reported as fold difference over ve-
hicle. Error bars are SEM. n=4 for each group. *=p<0.05.fects of metformin on AMPK activation in
the context of heart transplantations. West-
ern blot analysis illustrated that metformin
and AICAR treatment of the allograft in-
creased active phosphorylated AMPK levels
(Figure 3b), while total AMPK levels did not
change with treatment. This result indicates
that metformin activates AMPK signaling in
vivo, just as it does in vitro.
Activation of AMPK by Metformin or
AICAR Modulates Apoptosis in Cardiac
Grafts at POD 8
We next explored the specific pathways
by which metformin and AMPK may mod-
ulate  acute  rejection. The  two  pathways
studied were intrinsic apoptosis (through
mitochondrial release of cytochrome C) and
extrinsic apoptosis (through Fas death lig-
and). Each pathway was studied using a
representative  protein  marker(s)  (Figure
3c).
To analyze the intrinsic apoptosis path-
ways in the donor heart, we performed West-
ern blots for Bax and cleaved caspase-9. Bax
plays a role in the formation of mitochondr-
ial ion channels and subsequent cytochrome
C release. Thus, Bax is pro-apoptotic, pro-
moting the intrinsic apoptosis pathway. Both
metformin- and AICAR-treated grafts ex-
hibited decreased Bax compared to vehicle-
treated  grafts  (Figure  3d),  implying
decreased activation of the intrinsic apopto-
sis pathway.
Correlating with the Bax results, West-
ern  blot  showed  that  metformin-  and
AICAR-treated hearts had lower levels of
cleaved  caspase-9  than  vehicle-treated
hearts (Figure 3e). To rule out contributions
from extrinsic apoptosis, we performed a
Western blot for cleaved caspase-8 but did
not observe any trends or patterns. In partic-
ular, the levels of cleaved caspase-8 did not
vary  between  groups  (data  not  shown).
Taken together, the results imply that met-
formin and AICAR treatments down-regu-
late intrinsic apoptosis in allografts.
To quantify the downstream effects of in-
hibiting intrinsic apoptosis, caspase-3 activity
was measured in allografts using a fluoromet-
ric activity assay. Caspase-3 is a downstream
executor protease for apoptotic pathways, so
increased caspase-3 activity should signify
more robust apoptosis. The results of the cas-
pase-3 activity assay demonstrated that met-
formin  and AICAR  significantly  decrease
caspase-3 activity, as compared to the vehicle,
by 73.41 ﾱ 18.86 percent (p = 0.03) and 45.64
ﾱ 20.17 percent (p = 0.05), respectively (Fig-
ure 3f). Thus metformin and AICAR decrease
biomarkers of intrinsic apoptosis and caspase-
3 activity.
Metformin Treatment Decreases 
Apoptosis Acutely After Transplantation
Having  shown  that  metformin  and
AICAR similarly decrease intrinsic apopto-
sis in cardiac allografts, we next investi-
gated  the  cardioprotective  benefit  of
metformin  on  an  acute  rejection  time
course. To directly assess acute cell death in
grafted hearts, we performed a cytoplasmic
histone-associated DNA fragment cell death
detection ELISA (Roche). The colorimetric
signal detected in this ELISA corresponds
to histone-associated DNA fragments in the
sample, which are indicative of many dif-
ferent types of cell death. On POD 1 of the
time  course,  metformin-treated  grafts
showed  a  significant  reduction  (68.00  ﾱ
17.18 percent) in cell death compared to the
control (p = 0.007). On POD 8, metformin-
treated grafts showed a 63.80 ﾱ 35.76 per-
cent reduction compared to the control (p =
0.07) (Figure 4a). Therefore, 1 day and 8
days after transplantation, metformin treat-
ment exerted a protective effect on the allo-
graft by decreasing the amount of DNA
fragmentation, a sign of cell death.
However, the ELISA may not have been
able to differentiate between apoptosis and
necrosis, so we also performed a caspase-3
fluorescent activity assay. On both POD 1
and POD 8, metformin-treated grafts exhib-
ited significantly decreased caspase-3 activ-
ity compared to the vehicle-treated grafts
(POD 1: 44.83 ﾱ 7.57 percent, p = 0.001;
POD 8: 73.41 ﾱ 18.86 percent, p = 0.03)
(Figure 4b). Therefore, acutely after trans-
plantation on POD 1 and 8, metformin treat-
ment confers a cardioprotective effect on the
graft by significantly decreasing apoptosis.
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Chronically After Transplantation
After establishing metformin’s cardio-
protective mechanism in the acute rejection
time  course,  we  used  a  chronic  rejection
model to study the long-term effects of met-
formin  treatment  of  the  allograft.  In  this
model, animals treated with metformin had a
significant increase in their cardiac graft beat-
ing score (Figures 5a, b) and a significant de-
crease in CAV development (Figure 5c), as
measured by luminal narrowing (46.77 ﾱ 3.63
percent vs. 67.95 ﾱ 4.42 percent compared to
vehicle, respectively, p < 0.001). The long-
term effect of metformin pretreatment of a
cardiac allograft is improved beating function
and decreased CAV and chronic rejection.
DIsCussIoN
Here, we show that metformin results
in AMPK activation in vitro. Although car-
diomyocyte cell culture is not an in vitro
model of transplantation, we use it to prove,
in a defined system, that metformin leads to
increased pAMPK levels. Additionally, we
show  that  the  effects  of  metformin  on
pAMPK can be decreased by Compound C
(an ATP-competitive inhibitor) and that met-
formin’s effects are mimicked by AICAR
(an AMPK activator). In cardiac allografts,
metformin and AICAR also behave simi-
larly, leading to increased pAMPK but not
changing total AMPK levels. Thus, met-
formin seems to increase AMPK signaling
by  phosphorylation  and  activation  of
AMPK, and not by increasing total AMPK
levels.
We also show that metformin’s cardio-
protection is mimicked by AMPK activation
through AICAR.  In  cardiac  allografts  at
POD 8, both metformin and AICAR treat-
ment resulted in decreased cleaved, active
caspase-9 and pro-apoptotic Bax but did not
affect caspase-8 levels. We conclude that the
decrease in cell death from metformin and
AMPK activation results from a change in
intrinsic, rather than extrinsic, apoptosis (or
immune-mediated rejection).
Gross levels of Bax, as detected by
Western blot, may not be the most accurate
method for estimating intrinsic apoptosis
because Bax can exist in three different
forms: free in the cytosol, as a homodimer
in the outer mitochondrial membrane, and
as a heterodimer with Bcl-2 in the outer mi-
tochondrial membrane. Under normal con-
ditions, Bax is mainly found in the cytosol.
However, under apoptotic stimulation, Bax
undergoes conformational change and is in-
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Figure 4. Acute transplanta-
tion study: Decrease in graft
apoptosis from metformin
treatment. a) Histone-associ-
ated DNA Fragment ELISA (Cell
Death ELISA) using protein from
POD 1 and 8 graft hearts treated
with vehicle or metformin. Values
reported as fold difference over
vehicle. Error bars are SEM. n=4
for each group. *=p<0.05. b)
Caspase-3 fluorescent activity
assay using protein from POD 1
and POD 8 graft hearts treated
with vehicle or metformin. Values
reported as fold difference over
vehicle. Error bars are SEM. n=4
for each group. *=p<0.05.serted into the outer mitochondrial mem-
brane, where it forms a pro-apoptotic ho-
modimer  that  induces  pore  formation.
However, if Bax forms a heterodimer with
Bcl-2, Bax is incapacitated and cannot in-
crease  mitochondrial  membrane  perme-
ability. Therefore, we also used a caspase-3
activity assay to quantify the apoptotic ac-
tivity in the graft lysate. Both metformin
and AICAR treatment led to significantly
reduced caspase-3 activity, and thus signif-
icantly reduced apoptosis, as compared to
the vehicle. However, we cannot rule out
the possibility that metformin may protect
the heart in ways beyond AMPK pathway
modulation. Because metformin has been
shown to activate AMPK and treatment
with the AMPK agonist AICAR results in a
reduction in apoptosis similar to that with
metformin treatment, it follows that AMPK
activation may play a role in metformin’s
cardioprotective effects.
The cardioprotective effect of metformin
is not likely immune-mediated, since caspase-
8 levels and extrinsic apoptosis are unchanged.
Rather, the cardioprotective benefit of met-
formin likely stems from protection of the graft
from initial I-R injury during the transplanta-
tion procedure. However, there have been re-
ports implicating metformin in the inhibition
of proinflammatory responses, such as nuclear
factor-ʺB, in vascular wall cells [16]. Hence,
an alternative mode of metformin’s cardiopro-
tection may be through suppression of inflam-
matory immune responses. To rule out the
possibility that metformin works via an al-
loantigen-dependent route, future experiments
should also assess grafts for inflammatory cy-
tokines by ELISA and inflammatory infiltrates
by flow cytometry and histology. 
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Figure 5. Chronic
transplantation
study: Improve-
ment in graft func-
tion and decrease
in CAV from met-
formin treatment.
a) Time course of
cardiac graft beating
score up to POD 51
for control and met-
formin-treated
grafts. b) Average of
cardiac graft beating
scores for POD 10,
POD 30, and POD
52. Error bars are
SEM. n=6 for each
group. *=p<0.05. 
c) Percent luminal
narrowing for control
and metformin-
treated grafts on
POD 52. Error bars
are SEM. n=6 for
each group.
*=p<0.05. From  the  acute  transplantation  time
course, we conclude that both POD 1 and
POD 8 metformin-treated grafts resulted in
significantly  decreased  caspase-3  activity
compared to the control. Additionally, the
level of apoptosis in the graft was not differ-
ent between POD 1 and POD 8, despite the
extra injections of treatment for the grafts
harvested on POD 8. It is unclear whether the
extra treatments are necessary for metformin
to have therapeutic effect. Based on our hy-
pothesis that metformin protects the heart not
by suppressing immune-mediated rejection
but by decreasing I-R injury, we would ex-
pect that only the first metformin treatment at
the time of surgery is necessary to exert a
cardioprotective benefit. Therefore, in our
chronic transplantation study, we only treated
the graft during the operation and did not
treat the recipient animal with postoperative
metformin. Even after 52 days, the benefit of
metformin was still appreciable, as suggested
by decreased CAV and increased beat scores.
This supports our hypothesis that metformin
protects grafts from initial I-R injury from
the transplantation procedure. Notably, the
improvement in beat scores and CAV were
achieved with only one dose of metformin
and no immunosuppressive regimens.
In this study, we correlate a decrease in
initial  I-R  injury  and  apoptosis  with  de-
creased CAV and increased chronic graft
function, as a result of metformin treatment.
However, we do not show direct causation
since we use different models for the chronic
and acute studies. In future experiments, we
plan to measure in vivo apoptosis through
annexin V-SPECT at acute time points and
follow recipient animals to a chronic time
point to asses CAV.
Another possible area of future study is
the effect of metformin and AMPK on ROS-
induced  necrosis.  Indeed,  apoptosis  and
necrosis can both be stimulated by the in-
flammatory cytokine tumor necrosis factor-
ʱ,  which  is  upregulated  in  I-R  injury.
ROS-induced necrosis is another way by
which I-R injury contributes to development
of CAV. AMPK has been shown to decrease
the amount of ROS generated during peri-
ods of hypoxic stress, so it is possible that
metformin  also  protects  the  heart  from
chronic rejection and CAV by downregulat-
ing ROS-induced necrosis. Future studies
should examine whether metformin dimin-
ishes ROS-induced necrosis, a mechanism
through  which  metformin  may  decrease
CAV. Our results allow for this possibility
since we show in the acute time course that
metformin treatment decreases histone-as-
sociated DNA fragments, which may indi-
cate both apoptosis and necrosis.
Taken together, the results of this study
represent  a  novel  approach  to  improving
chronic outcomes in cardiac transplantation
without  immunosuppression.  We  demon-
strate that metformin activates AMPK, which
then prevents acute cell death in cardiac allo-
grafts  by  primarily  suppressing  intrinsic
apoptosis due to I-R injury incurred from the
transplantation procedure. The pathway mod-
ulated by AMPK is likely intrinsic apoptosis,
rather than extrinsic apoptosis, since the car-
dioprotective mechanism of metformin and
AMPK is maintenance of the energy supply
during ischemic stress. Metformin’s suppres-
sion of I-R injury in the acute rejection model
correlates with a metformin-associated de-
crease in CAV in the chronic rejection model.
These results suggest that metformin’s long-
term graft cardioprotection may stem from
decreasing initial I-R injury, and not from im-
munosuppression. Meanwhile, AMPK, the
key regulatory protein under investigation,
may be involved in many diseases, such as
obesity, cancer, diabetes, and heart disease.
Thus, new insights regarding the relationship
between AMPK, metformin, and intrinsic
apoptosis will not only enhance the long-term
efficacy and safety of heart transplants, but
will also contribute to progress in many med-
ical research areas.
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